바이오톡스텍

086040KOSDAQ자연과학 및 공학 연구개발업

55.8 / 100

Reference Date: 2026-06-10

Financial Score22.5 / 40

News Sentiment21.3 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 22.4% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

BioToxtek specializes in non-clinical CRO services, conducting toxicity and safety/efficacy evaluations using rodents and primates for pharmaceuticals, cell therapies, and chemicals. The company actively participates in new material development and is advancing the commercialization of therapeutic candidates like TB-4 and HX-1171 through technology licensing.

Number of Employees

241people

Average Salary

47.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

33.18Industry Average 62.706.5Point

Lower than industry avg (good)

PBR

1.23Industry Average 3.247.0Point

Half of industry avg (excellent)

ROE

-4.74Industry Average -32.093.5Point

Well below industry avg

Debt Ratio

44.42Industry Average 7.310.0Point

6.1x industry avg (risky)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲20.2% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲18.7% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -18.2% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
바이오톡스텍 "올해 흑자전환 원년…글로벌 CRO로 도약할 것"[코스닥人...
바이오톡스텍이 올해 흑자 전환을 목표로 하며, 글로벌 CRO로의 성장과 함께 키프라임리서치의 코스닥 상장 준비로 긍정적 전망을 보임.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 2,455Won52-week high 3,92552-week low 2,455

1-month return0.0Point

1m -22.43% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-15